iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
iRhythm Holdings (IRTC) reported Q2 2026 adjusted EPS of 58 cents versus an adjusted loss of 32 cents a year earlier, beating the Zacks Consensus Estimate by 5900%. Revenue rose 20.1% to $224.2 million. Gross margin increased to 72.8%. Full-year 2026 revenue guidance was raised to $880 million-$890 million and adjusted EBITDA margin to 13%-14%.
How this was made
The 30-second read
Why it matters
The combination of a Q2 adjusted EPS beat, raised full-year revenue and EBITDA margin guidance, FDA clearance for a third-generation algorithm, and an agreement to acquire Vital Connect provides multiple near-term valuation catalysts.
Market read
Traders can update models immediately using the raised 2026 revenue range and adjusted EBITDA margin range, plus the acquisition and FDA clearance as execution catalysts.
What to watch
The article highlights margin expansion and expense trends, but does not quantify how much of the EBITDA margin improvement is sustainable versus one-time operational effects.
Background
iRhythm is a cardiac monitoring and related healthcare analytics provider, reporting Q2 results and updating its 2026 outlook.
Ticker impact
iRhythm reported Q2 adjusted EPS of 58 cents and raised 2026 revenue guidance to $880 million-$890 million.
Near-term upside bias as traders price in higher 2026 revenue and margin, with follow-through dependent on execution of the Vital Connect acquisition and algorithm cost-savings realization.
The article discloses multiple fresh catalysts: Q2 beat, explicit 2026 outlook increase, and new FDA clearance plus a $287.5 million acquisition agreement. These are typically sufficient for a sustained post-earnings repricing, though the magnitude of the move is not provided here.
Market effects
Cardiac monitoring and health-tech peers may see read-across interest if iRhythm’s volume growth and margin expansion appear durable.
Primarily US healthcare services/diagnostics sentiment; limited direct regional spillover described.
International expansion is mentioned, but no specific foreign regulatory or commercial milestone is disclosed.
Counterpoint
Guidance raises could be partially offset by integration risk from the Vital Connect acquisition and timing risk around algorithm-driven technician time reduction and cost savings.
Key entities
- companyiRhythm Holdings, Inc.
Reported Q2 2026 results, raised 2026 revenue and adjusted EBITDA margin outlook, received FDA clearance, and agreed to acquire Vital Connect.
- companyVital Connect
Target of an agreement to acquire for approximately $287.5 million to broaden cardiac monitoring portfolio.
- regulatorFDA
Cleared iRhythm’s third-generation algorithm expected to reduce technician review time and generate cumulative cost savings.
